Analysts Anticipate Assembly Biosciences Inc (NASDAQ:ASMB) to Post -$1.10 Earnings Per Share

Share on StockTwits

Wall Street brokerages expect Assembly Biosciences Inc (NASDAQ:ASMB) to report ($1.10) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for Assembly Biosciences’ earnings. The lowest EPS estimate is ($1.18) and the highest is ($1.02). Assembly Biosciences reported earnings of ($1.30) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 15.4%. The firm is scheduled to announce its next earnings results on Wednesday, August 14th.

According to Zacks, analysts expect that Assembly Biosciences will report full year earnings of ($4.34) per share for the current year, with EPS estimates ranging from ($4.91) to ($4.01). For the next year, analysts anticipate that the firm will report earnings of ($4.65) per share, with EPS estimates ranging from ($5.80) to ($3.86). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.01. The company had revenue of $3.89 million during the quarter, compared to analysts’ expectations of $3.81 million. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%.

Several research firms have issued reports on ASMB. Zacks Investment Research cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday. BidaskClub lowered shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Monday. William Blair restated an “outperform” rating on shares of Assembly Biosciences in a report on Friday, May 10th. Finally, Chardan Capital restated a “hold” rating and issued a $30.00 price target on shares of Assembly Biosciences in a report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $41.20.

Assembly Biosciences stock traded down $0.49 during trading hours on Wednesday, hitting $13.37. The company had a trading volume of 199,765 shares, compared to its average volume of 278,374. The company has a market cap of $329.59 million, a price-to-earnings ratio of -3.35 and a beta of 1.61. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.97 and a current ratio of 7.97. Assembly Biosciences has a 1 year low of $12.75 and a 1 year high of $44.65. The business’s 50-day simple moving average is $15.00.

Several large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in shares of Assembly Biosciences by 87,340.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,372 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 4,367 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Assembly Biosciences by 17.0% during the 4th quarter. Legal & General Group Plc now owns 3,847 shares of the biopharmaceutical company’s stock worth $87,000 after acquiring an additional 558 shares in the last quarter. Marshall Wace North America L.P. raised its stake in shares of Assembly Biosciences by 191.5% during the 1st quarter. Marshall Wace North America L.P. now owns 4,431 shares of the biopharmaceutical company’s stock worth $87,000 after acquiring an additional 2,911 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its stake in shares of Assembly Biosciences by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,073 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 5,524 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. raised its stake in shares of Assembly Biosciences by 10.4% during the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 15,344 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 1,447 shares in the last quarter. Institutional investors and hedge funds own 86.44% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Featured Article: Balance Sheet

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bank of America Boosts Energy Transfer LP Unit  Price Target to $24.00
Bank of America Boosts Energy Transfer LP Unit Price Target to $24.00
FedEx  Price Target Lowered to $175.00 at Raymond James
FedEx Price Target Lowered to $175.00 at Raymond James
Gain Capital  Coverage Initiated by Analysts at B. Riley
Gain Capital Coverage Initiated by Analysts at B. Riley
Goldman Sachs Group Reiterates Buy Rating for Caci International
Goldman Sachs Group Reiterates Buy Rating for Caci International
Jefferies Financial Group Increases Capri  Price Target to $80.00
Jefferies Financial Group Increases Capri Price Target to $80.00
Aircastle  Raised to “Strong-Buy” at Zacks Investment Research
Aircastle Raised to “Strong-Buy” at Zacks Investment Research


 
© 2006-2019 Zolmax.